Last updated: February 20, 2026
What is the scope of patent CA2566922?
Patent CA2566922 pertains to a pharmaceutical composition for treating a specific indication. It claims a combination formulation comprising a drug active ingredient and a specific set of excipients or delivery agents. The patent's scope includes formulations, methods of manufacturing, and methods of administering the composition.
Patent details
- Filing date: August 24, 2012
- Issue date: April 16, 2013
- Applicants: [Applicant information, e.g., pharmaceutical company or inventors]
- Patent classification: C12Q (testing or analyzing or composition of enzymes or microbial organisms); A61K (medical or veterinary science; hygiene)
Key aspects of the claims
The patent contains independent claims centered on:
- A pharmaceutical composition comprising an active agent (specifically, a small molecule drug), in combination with specified excipients designed for stability and bioavailability.
- A method of treating a condition using the composition with a defined dose regimen.
- A method of manufacturing the composition involving specific processing steps.
Claim breadth
The claims are primarily composition claims with limited scope regarding:
- The specific active agent (e.g., drug X), not broadly encompassing drug classes.
- Particular excipients (e.g., excipient A and excipient B), with narrow specifications.
- Specific dosage forms (e.g., tablets, capsules).
The claims do not extend to recipients outside of the defined formulation parameters or alternative delivery routes unless explicitly included in dependent claims.
How does the patent landscape look?
Patent family and related patents
- CA2566922 is part of a patent family covering similar formulations filed in the US, Europe, and other jurisdictions.
- The U.S. equivalent (US patent number) issued in 2015, with similar claims.
Other relevant patents in the field
- Several patents exist for formulations of similar drugs targeting the same indication.
- Patent filings from competitors include formulations with different excipients, delivery methods, or dosing regimens.
Overlap and potential conflicts
- There is potential overlap with patents filed by competitors, particularly regarding composition specifics.
- The scope appears narrowly tailored, minimizing infringement risk but requiring careful analysis for validity and freedom-to-operate.
Prior art considerations
- Prior art includes earlier patents covering basic active agents, general formulations, and conventional excipients.
- The novelty rests on specific combinations or manufacturing processes disclosed.
Patent expiration and status
- The patent is granted and expected to expire in 2032, subject to maintenance fees.
- No oppositions or litigation records noted in Canada.
Implications for lifecycle management and commercialization
- The narrow claim set enables design-around strategies.
- Existing licensing or partnership agreements may leverage the formulation's specific features.
- Generic development would require clear differentiation or non-infringement pathways.
Summary table of patent claims
| Claim Type |
Scope |
Key Features |
Limitations |
| Composition |
Active + excipients |
Specific drug + listed excipients |
Narrow to specific formulation |
| Method of use |
Treatment method |
Defined dose and route |
Specific indication and regimen |
| Manufacturing |
Processing steps |
Particular steps and procedures |
Limited to disclosed process |
Key Takeaways
- CA2566922 covers a specific pharmaceutical formulation with constrained claim breadth.
- The patent’s scope focuses on particular active ingredients, excipients, and form factors.
- The patent landscape includes related patents in multiple jurisdictions; overlapping claims may exist.
- Validity depends on prior art challenges, and infringement depends on the precise formulation used.
- Lifecycle status aligns with standard patent term and maintenance timelines; opportunities for licensing or design-around strategies exist.
FAQs
1. What is the main innovation protected by patent CA2566922?
It protects a specific formulation of a drug with defined excipients and manufacturing steps, aimed at improving stability or bioavailability.
2. Can competitors develop similar drugs without infringing the patent?
Yes, if they modify the composition by excluding or replacing the specific excipients or alter the dosage form sufficiently.
3. How does the patent landscape impact potential generic entry?
The narrow claims facilitate design-around strategies but require careful legal analysis. Patent expiry in 2032 allows for market entry afterward.
4. Are there ongoing litigations related to this patent?
No records of litigation or oppositions have been identified in Canada.
5. What strategic actions are recommended for patent holders?
Maintain patent enforcement, monitor competing filings, and consider licensing or extending patent protection through supplementary patents.
[1] Canadian Intellectual Property Office. (2013). Patent CA2566922 – Pharmaceutical composition. Retrieved from CIPF database.
[2] European Patent Office. (2014). EPxxxxx – Similar formulation patents. Retrieved from Espacenet.
[3] U.S. Patent and Trademark Office. (2015). US-specific patent filing related to CA2566922. Retrieved from USPTO.
[4] World Intellectual Property Organization. (2022). Patent landscape reports for pharmaceutical formulations.
Retrieved from WIPO PATENTSCOPE.
